Physician profile
Lawrence E Blase
NPI 1265419204
$1,699.47
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $342 · 2021: $551 · 2022: $352.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $543.67 | 2019-2021 | |
| Lilly USA, LLC | $151.09 | 2019-2022 | |
| Novo Nordisk INC | $101.46 | 2019-2021 | |
| Abbvie INC. | $98.18 | 2021-2022 | |
| Glaxosmithkline, LLC. | $95.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $89.52 | 2020-2021 | |
| Esperion Therapeutics, INC. | $81.46 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $77.37 | 2021 | |
| Pulmonx Corporation | $75.79 | 2021 | |
| Astellas Pharma US INC | $74.94 | 2019-2021 | |
| Abbott Laboratories | $60.28 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $38.19 | 2022 | |
| Upsher-Smith Laboratories LLC | $36.74 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $34.33 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.00 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Promius Pharma LLC | $21.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.77 | 2021 | |
| Seqirus USA INC | $15.42 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.91 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Blase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.